{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '9. STATISTICS', '9.1', 'Determination of Sample Size', 'All subjects who previously completed 24 weeks of double-blind treatment in the core', 'studies will be eligible to enroll in this OLE study. It is estimated that approximately', '1880 subjects will be randomized in the OLE study to 1 of 2 treatment groups (OKZ 64 mg', 'q4w or OKZ 64 mg q2w) in a 1:1 ratio.', '9.2', 'Data to be Analyzed', \"Data handling will be the responsibility of R-Pharm International's designee. The data will\", 'be inspected for inconsistencies by performing validation checks.', '9.3', 'Analysis Populations', 'Safety Population: The Safety population will include all subjects who receive at least', '1 dose of study treatment during the OLE study. Subjects in the Safety population will', 'be analyzed according to the treatment they actually received.', '- A combined analysis of safety data from all subjects participating in the core studies', 'and the OLE study will be conducted separately and details will be included in a', 'separate Statistical Analysis Plan (SAP) for an Integrated Summary of Safety (ISS).', 'Results of the ISS will be reported separately and will not be included in the Clinical', 'Study Report of this study.', 'Modified Intent-to-Treat (mITT) Population: The mITT population will include all', 'subjects who sign an ICF for participation in the OLE study, are randomized in the', 'OLE study, and receive at least 1 dose of study treatment in the OLE study. Subjects', 'will be analyzed according to the treatment group to which they were randomized in', 'the OLE study. The mITT population will be the primary efficacy analysis', 'population.', 'Per Protocol (PP) Population: The PP population will include all mITT subjects who', 'do not have any major protocol violations. Subjects will be analyzed according to the', 'OLE treatment group to which they were randomized. Major protocol violations and', 'the inclusion of subjects in the PP population will be finalized prior to database lock.', 'The PP population will be used for supportive analyses of selected efficacy endpoints.', 'Amendment 2: 06 March 2019', '123', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '9.4', 'Statistical Methods', 'This section provides a high-level description of the analyses planned in this study. Details', 'of any analysis, interim or final, will be specified in the SAP, to be written and finalized prior', \"to database lock. The statistical analysis will be performed by R-Pharm International's\", 'designee. All statistical analyses will be conducted using SASR version 9.2 or higher for', 'Windows.', 'All data collected in the clinical database will be presented in subject data listings.', 'Data collected after the modification of background therapy (as described in Section 6.13.3)', 'will be used in all analyses.', 'Data collected during the core studies for subjects enrolled in the OLE study may be', 'programmatically combined with the OLE study database for selected analyses.', 'All analyses of safety and efficacy will be descriptive; no inferential analyses will be', 'performed.', 'Continuous endpoints will be summarized using descriptive statistics such number of', 'available values (n), mean, median, minimum, maximum, and standard deviation in each', 'treatment group and overall, as appropriate. Categorical endpoints will be summarized by', 'the number and percentage of subjects in each category.', 'Data will be summarized based on treatment groups reflecting randomized or actual', 'treatment (for efficacy or safety analyses, respectively) during the core and OLE studies as', 'follows:', 'a. OKZ 64 mg q4w (OLE): All subjects in the OKZ 64 mg q4w group in the OLE', 'b. OKZ 64 mg q2w (OLE): All subjects in the OKZ 64 mg q2w group in the OLE', 'c.', 'OKZ 64 mg q4w (core/OLE): Subjects from the OKZ 64 mg q4w group in the core', 'study and continuing on OKZ 64 mg q4w in OLE. For subjects enrolling from the', 'CL04041025 core study, inclusion in the OKZ 64 mg q4w group in the core study', 'will be based on the initial treatment period prior to Week 16 (i.e., placebo subjects', 're-randomized to receive OKZ 64 mg q4w at Week 16 will not be included in this', 'group).', 'd. OKZ 64 mg q2w (core/OLE): Subjects from the OKZ 64 mg q2w group in the core', 'study and continuing on OKZ 64 mg q2w in OLE. For subjects enrolling from the', 'CL04041025 core study, inclusion in the OKZ 64 mg q2w group in the core study', 'will be based on the initial treatment period prior to Week 16 (i.e., placebo subjects', 'Amendment 2: 06 March 2019', '124', 'Confidential']\n\n###\n\n", "completion": "END"}